Registered title, quoted from ClinicalTrials.gov
CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD
An open trial on coronary heart disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06820970, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) < 30%
Exclusion criterion 2
Creatinine clearance <15 mL/min (or eGFR < 15 mL/min/1.73m²), or requires dialysis
Exclusion criterion 3
Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal
Exclusion criterion 7
History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; day-to-day activity level; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06820970, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1) Age ≥18 years old
- 2) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) < 0.80)
- 3) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);
Exclusion Criteria:
- Age < 18 years old
- Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) < 30%
- Creatinine clearance <15 mL/min (or eGFR < 15 mL/min/1.73m²), or requires dialysis
- Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.
- Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs)
- Poorly controlled hypertension (SBP > 180 mm Hg or DBP > 110 mm Hg)
- Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal
- Unexplained CK > 5 times the upper limit of normal, or elevated CK due to known muscle disease
- Planned or anticipated cardiac surgery or revascularization before randomization
- History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
- Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis
- Hearing impairment, unable to undergo mindfulness therapy
- Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug
- Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)
- Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study
- History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)
- Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study
- As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.
Quoted from ClinicalTrials.gov, NCT06820970, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06820970, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.